Mizuho Securities analyst Mara Goldstein maintained a Buy rating on TCR2 Therapeutics (TCRR – Research Report) today and set a price target of $51.00. The company’s shares closed last Thursday at $15.72, close to its 52-week low of $12.15.
According to TipRanks.com, Goldstein is a 4-star analyst with an average return of 13.0% and a 39.7% success rate. Goldstein covers the Healthcare sector, focusing on stocks such as Adaptimmune Therapeutics, Iovance Biotherapeutics, and Corvus Pharmaceuticals.
TCR2 Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $38.60.
TCR2 Therapeutics’ market cap is currently $600.4M and has a P/E ratio of -7.00. The company has a Price to Book ratio of 1.89.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
TCR2 Therapeutics, Inc. is an immunotherapy company, which develops biological drugs and engineering T-cells for cancer therapy. The company offers cancer therapy, T-cell biology, Immunology and Molecular biology. It also engages in the research and collaboration with academic laboratories and industry partners in the field of T-cell immunology, cell therapy, gene editing, and process development. The company was founded in May 2015 and is headquartered in Cambridge, MA.